CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 80 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,293,720 | +1112.7% | 312,499 | +634.8% | 0.00% | – |
| Q2 2023 | $766,355 | +50218.8% | 42,528 | -55.1% | 0.00% | -100.0% |
| Q1 2023 | $1,523 | -85.5% | 94,807 | -83.5% | 0.00% | -83.3% |
| Q4 2022 | $10,531 | -99.8% | 575,488 | +78.9% | 0.01% | +50.0% |
| Q3 2022 | $6,319,000 | -33.5% | 321,752 | -36.8% | 0.00% | -33.3% |
| Q2 2022 | $9,499,000 | +83.2% | 509,330 | +115.7% | 0.01% | +100.0% |
| Q1 2022 | $5,184,000 | +453.8% | 236,160 | +616.5% | 0.00% | – |
| Q4 2021 | $936,000 | +267.1% | 32,959 | +172.1% | 0.00% | – |
| Q3 2021 | $255,000 | +24.4% | 12,112 | -16.7% | 0.00% | – |
| Q4 2020 | $205,000 | -89.6% | 14,538 | -87.1% | 0.00% | -100.0% |
| Q2 2020 | $1,980,000 | +337.1% | 113,034 | +526.5% | 0.00% | +200.0% |
| Q4 2019 | $453,000 | -45.4% | 18,041 | -67.3% | 0.00% | 0.0% |
| Q3 2019 | $829,000 | +310.4% | 55,149 | +520.5% | 0.00% | – |
| Q1 2019 | $202,000 | – | 8,888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |